Journal of the Korean Society of Radiology (대한영상의학회지)

The Korean Society of Radiology (대한영상의학회)
권호 표지
DOI QR코드

DOI QR Code

Atherectomy in Peripheral Artery Disease: Current and Future

말초동맥질환에서의 죽종절제술: 현재와 미래

  • Yohan Kwon (Department of Radiology, Ajou University Hospital) ;
  • Jinoo Kim (Department of Radiology, Ajou University Hospital) ;
  • Je-Hwan Won (Department of Radiology, Ajou University Hospital) ;
  • Seong Ho Kim (Department of Radiology, Ajou University Hospital) ;
  • Jeong-Eun Kim (Department of Radiology, Ajou University Hospital) ;
  • Sung-Joon Park (Department of Radiology, Korea University Ansan Hospital)
  • 권요한 (아주대학교병원 영상의학과) ;
  • 김진우 (아주대학교병원 영상의학과) ;
  • 원제환 (아주대학교병원 영상의학과) ;
  • 김성호 (아주대학교병원 영상의학과) ;
  • 김정은 (아주대학교병원 영상의학과) ;
  • 박성준 (고려대학교 안산병원 영상의학과)
  • Received : 2021.02.23
  • Accepted : 2021.04.02
  • Published : 2021.05.01
Download PDF
⟨ Previous Next ⟩

Abstract

Atherectomy has become a promising treatment option for peripheral artery disease caused by diabetes mellitus or end-stage renal disease. Atherectomy refers to the removal of atheromatous tissue by mechanical method, resulting in an enlarged lumen of the treated blood vessel. Based on this method, the term is limited to the percutaneous minimally invasive approach, and there are currently two types of atherectomy devices available in Korea. The increased prevalence of atherectomy has led to the concept of "vascular preparation" and a new treatment concept of "leave nothing behind." Various studies have proven the safety and effectiveness of atherectomy; however, there are some limitations. We need to remain focused on patient selection and subsequent large-scale research.

죽종절제술은 당뇨병과 만성콩팥병증 등에 의해 발생하는 말초동맥질환에서 유망한 치료법이다. 죽종절제술은 기계적 방법을 통해 죽종 조직을 제거하여 혈관의 내경을 확대하는 것을 말한다. 방법의 특성상 주로 경피적 미세 침습 접근 방식에 국한하여 통용되는 용어이며, 현재 한국에서 사용 가능한 죽종절제술 장치는 두 가지가 있다. 죽종절제술이 성행하면서 "혈관 준비"라는 개념과 "아무것도 남기지 않기"라는 새로운 치료 개념이 대두되었다. 다양한 연구들이 죽종제거술의 안전성과 효용성을 증명하고 있지만 그 한계도 존재하므로, 환자 선택에 신중을 기할 필요가 있고 후속적인 대규모의 연구가 필요하다.

Keywords

References

  1. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011;124:17-23 
  2. Yu JH, Hwang JY, Shin MS, Jung CH, Kim EH, Lee SA, et al. The prevalence of peripheral arterial disease in korean patients with type 2 diabetes mellitus attending a university hospital. Diabetes Metab J 2011;35:543-550 
  3. Lim S, Kim DJ, Jeong IK, Son HS, Chung CH, Koh G, et al. A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: The Committee of the Korean Diabetes Association on the Epidemiology of Diabetes Mellitus. Korean Diabetes J 2009;33:48-57 
  4. Son JY, Kim GY, Lee JY, Kim DH. Prevalence of peripheral arterial disease (PAD) used by edinburgh claudication questionnaire among the elderly people in rural communities. J Prev Med Public Health 1995;28:364-372 
  5. Fontaine R. Surgical treatment of peripheral circulation disorders. Helv Chir Acta 1954;21:499-533 
  6. Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997;26:517-538 
  7. Mills JL Sr, Conte MS, Armstrong DG, Pomposelli FB, Schanzer A, Sidawy AN, et al. The society for vascular surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014;59:220-234.e1-2 
  8. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645-681 
  9. Dake MD, Scheinert D, Tepe G, Tessarek J, Fanelli F, Bosiers M, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 2011;18:613-623 
  10. Laird JR, Katzen BT, Scheinert D, Lammer J, Carpenter J, Buchbinder M, et al. Nitinol stent implantation versus balloon angioplasty for lesions in the superficial femoral artery and proximal popliteal artery: twelvemonth results from the RESILIENT randomized trial. Circ Cardiovasc Interv 2010;3:267-276 
  11. Schillinger M, Sabeti S, Dick P, Amighi J, Mlekusch W, Schlager O, et al. Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. Circulation 2007;115:2745-2749 
  12. Caradu C, Lakhlifi E, Colacchio EC, Midy D, Berard X, Poirier M, et al. Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease. J Vasc Surg 2019;70:981-995.e10 
  13. Dick P, Wallner H, Sabeti S, Loewe C, Mlekusch W, Lammer J, et al. Balloon angioplasty versus stenting with nitinol stents in intermediate length superficial femoral artery lesions. Catheter Cardiovasc Interv 2009;74:1090-1095 
  14. Vroegindeweij D, Vos LD, Tielbeek AV, Buth J, vd Bosch HC. Balloon angioplasty combined with primary stenting versus balloon angioplasty alone in femoropopliteal obstructions: a comparative randomized study. Cardiovasc Intervent Radiol 1997;20:420-425 
  15. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation 2016;133:1472-1483 
  16. Rocha-Singh KJ, Zeller T, Jaff MR. Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv 2014;83:E212-E220 
  17. Korosoglou G, Lichtenberg M, Celik S, Andrassy J, Brodmann M, Andrassy M. The evolving role of drug-coated balloons for the treatment of complex femoropopliteal lesions. J Cardiovasc Surg (Torino) 2017;59:51-59 
  18. Loffroy R, Chevallier O, Falvo N, Gehin S, Midulla M, Galland C. Combined HawkOne directional atherectomy and paclitaxel-coated balloon angioplasty for isolated calcified popliteal artery lesion: a no-stent approach to lower extremity endovascular revascularization. Quant Imaging Med Surg 2018;8:364-367 
  19. Shammas NW, Coiner D, Shammas GA, Dippel EJ, Christensen L, Jerin M. Percutaneous lower-extremity arterial interventions with primary balloon angioplasty versus Silverhawk atherectomy and adjunctive balloon angioplasty: randomized trial. J Vasc Interv Radiol 2011;22:1223-1228 
  20. McKinsey JF, Zeller T, Rocha-Singh KJ, Jaff MR, Garcia LA; DEFINITIVE LE Investigators. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv 2014;7:923-933 
  21. Garcia LA, Jaff MR, Rocha-Singh KJ, Zeller T, Bosarge C, Kamat S, et al. A comparison of clinical outcomes for diabetic and nondiabetic patients following directional atherectomy in the DEFINITIVE LE Claudicant cohort. J Endovasc Ther 2015;22:701-711 
  22. Rastan A, McKinsey JF, Garcia LA, Rocha-Singh KJ, Jaff MR, Noory E, et al. One-year outcomes following directional atherectomy of infrapopliteal artery lesions: subgroup results of the prospective, multicenter DEFINITIVE LE trial. J Endovasc Ther 2015;22:839-846 
  23. Rastan A, McKinsey JF, Garcia LA, Rocha-Singh KJ, Jaff MR, Harlin S, et al. One-year outcomes following directional atherectomy of popliteal artery lesions: subgroup analysis of the prospective, multicenter DEFINITIVE LE trial. J Endovasc Ther 2018;25:100-108 
  24. Roberts D, Niazi K, Miller W, Krishnan P, Gammon R, Schreiber T, et al. Effective endovascular treatment of calcified femoropopliteal disease with directional atherectomy and distal embolic protection: final results of the DEFINITIVE Ca++ trial. Catheter Cardiovasc Interv 2014;84:236-244 
  25. Zeller T, Langhoff R, Rocha-Singh KJ, Jaff MR, Blessing E, Amann-Vesti B, et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv 2017;10:e004848 
  26. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-699 
  27. Cioppa A, Stabile E, Salemme L, Popusoi G, Pucciarelli A, Iacovelli F, et al. Combined use of directional atherectomy and drug-coated balloon for the endovascular treatment of common femoral artery disease: immediate and one-year outcomes. EuroIntervention 2017;12:1789-1794 
  28. Zeller T, Krankenberg H, Steinkamp H, Rastan A, Sixt S, Schmidt A, et al. One-year outcome of percutaneous rotational atherectomy with aspiration in infrainguinal peripheral arterial occlusive disease: the multicenter pathway PVD trial. J Endovasc Ther 2009;16:653-662 
  29. Sixt S, Rastan A, Scheinert D, Krankenberg H, Steinkamp H, Schmidt A, et al. The 1-year clinical impact of rotational aspiration atherectomy of infrainguinal lesions. Angiology 2011;62:645-656 
  30. Mehta M, Zhou Y, Paty PS, Teymouri M, Jafree K, Bakhtawar H, et al. Percutaneous common femoral artery interventions using angioplasty, atherectomy, and stenting. J Vasc Surg 2016;64:369-379 
  31. Gray WA, Garcia LA, Amin A, Shammas NW; JET Registry Investigators. Jetstream Atherectomy System treatment of femoropopliteal arteries: results of the post-market JET Registry. Cardiovasc Revasc Med 2018;19:506-511 
  32. Banerjee A, Sarode K, Mohammad A, Brilakis ES, Banerjee S, Shammas GA, et al. Safety and effectiveness of the Nav-6 filter in preventing distal embolization during jetstream atherectomy of infrainguinal peripheral artery lesions. J Invasive Cardiol 2016;28:330-333 
  33. Shammas NW, Shammas GA, Jones-Miller S, Shammas WJ, Bou-Dargham B, Shammas AN, et al. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: a single center experience (JET-SCE). Cardiovasc Revasc Med 2018;19:771-777 
  34. Shammas NW, Shammas GA, Banerjee S, Popma JJ, Mohammad A, Jerin M. JetStream rotational and aspiration atherectomy in treating in-stent restenosis of the femoropopliteal arteries: results of the JETSTREAM-ISR feasibility study. J Endovasc Ther 2016;23:339-346 
  35. Shammas NW, Petruzzi N, Henao S, Armstrong EJ, Shimshak T, Banerjee S, et al. JetStream atherectomy for the treatment of in-stent restenosis of the femoropopliteal segment: one-year results of the JET-ISR study. J Endovasc Ther 2021;28:107-116 
  36. Davis T, Ramaiah V, Niazi K, Martin Gissler H, Crabtree T. Safety and effectiveness of the Phoenix Atherectomy System in lower extremity arteries: early and midterm outcomes from the prospective multicenter EASE study. Vascular 2017;25:563-575 
  37. Azar Y, DeRubertis B, Baril D, Woo K. Atherectomy-associated complications in the southern california vascular outcomes improvement collaborative. Ann Vasc Surg 2018;49:241-246 
  38. Wardle BG, Ambler GK, Radwan RW, Hinchliffe RJ, Twine CP. Atherectomy for peripheral arterial disease. Cochrane Database Syst Rev 2020;9:CD006680